Showing results (221-230 of 407) with videos related to
Sort By:
Pageof 41
Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.Annals of the Rheumatic Diseases|March 24, 2012
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trialIn-Ho Song, Christian E Althoff, Hildrun Haibel, et al.Annals of the Rheumatic Diseases|February 9, 2020
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAlexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, et al.Arthritis Research & Therapy|February 18, 2009
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patientsKatharina Hanke, Claudia S Brückner, Cornelia Dähnrich, et al.Rheumatology (Oxford, England)|July 18, 2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-upRoy Fleischmann, Mark C Genovese, Yong Lin, et al.Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.Journal of Autoimmunity|January 15, 2023
Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patientsAlexander Ten Hagen, Sandra Hermann, Elisa Habermann, et al.Annals of the Rheumatic Diseases|March 12, 2017
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisJackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, et al.Medicine|May 9, 2020
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumabMarc Schmalzing, Frank Behrens, Eva C Schwaneck, et al.Rheumatology (Oxford, England)|July 17, 2018
Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabFrank Behrens, Michaela Koehm, Eva C Schwaneck, et al.Pageof 41